Preclinical development of Q2361, a transforming new drug for skin cancer prevention in organ transplant recipients

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/2000135

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients that receive organ transplants need additional medications in order to prevent organ rejection. Unfortunately, these drugs carry an unwanted side-effect - they permit the development of skin cancer. Currently, other than surgery, little can be done to help these patients. Our preliminary data suggest that a new drug may prevent these skin cancers from forming. This project aims to deliver key insights into the influence of this drug and its role in skin cancer prevention.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: Development Grants

Funding Amount: $724,957.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer prevention | drug development | skin cancer | squamous cell carcinoma

Related Links